Financial reports
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
10-K/A
2022 FY
Annual report (amended)
14 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
3 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
Current reports
8-K
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023
14 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
16 Feb 24
8-K
Entry into a Material Definitive Agreement
31 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
8-K
Other Events
19 Dec 23
8-K
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
2 Nov 23
8-K/A
Departure of Directors or Certain Officers
17 Oct 23
8-K
Departure of Directors or Certain Officers
16 Oct 23
8-K
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
2 Aug 23
8-K
Other Events
21 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
14 Mar 24
S-3
Shelf registration
14 Mar 24
POSASR
Automatic shelf registration (post-effective amendment)
14 Mar 24
424B5
Prospectus supplement for primary offering
2 Nov 23
S-8
Registration of securities for employees
28 Feb 23
S-3ASR
Automatic shelf registration
2 Nov 22
SC TO-I/A
Issuer tender offer statement (amended)
20 Jul 22
SC TO-I/A
Issuer tender offer statement (amended)
12 Jul 22
SC TO-I
Issuer tender offer statement
21 Jun 22
SC TO-C
Information about tender offer
14 Apr 22
Proxies
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
PRE 14A
Preliminary proxy
14 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEFA14A
Additional proxy soliciting materials
23 Apr 20
Other
CT ORDER
Confidential treatment order
25 Oct 21
EFFECT
Notice of effectiveness
11 Oct 18
CT ORDER
Confidential treatment order
11 Oct 18
CERT
Certification of approval for exchange listing
10 Oct 18
CORRESP
Correspondence with SEC
4 Oct 18
CORRESP
Correspondence with SEC
4 Oct 18
CORRESP
Correspondence with SEC
2 Oct 18
CORRESP
Correspondence with SEC
26 Sep 18
UPLOAD
Letter from SEC
26 Sep 18
CORRESP
Correspondence with SEC
14 Sep 18
Ownership
4
TIMOTHY L. MOORE
24 Apr 24
144
Notice of proposed sale of securities
22 Apr 24
4
David D Chang
18 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
Geoffrey M. Parker
6 Mar 24
SC 13G/A
Belldegrun Arie
14 Feb 24
SC 13G/A
Chang David D
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
TIMOTHY L. MOORE
31 Jan 24